Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

437.15 +2.63 (+0.61%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

68 69 Next >

3 Gene Editing Stocks That Could Grow Your Wealth ↗

July 17, 2024

Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks.

Via InvestorPlace

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗

July 16, 2024

CRISPR Therapeutics could start reporting product revenue soon.

Via The Motley Fool

Bull Market and Beyond: 2 Stocks Just Waiting to Soar ↗

July 15, 2024

These innovative drugmakers are hard to ignore.

Via The Motley Fool

Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split ↗

July 15, 2024

Revenue is climbing at these two drug companies -- and the trend should continue.

Via The Motley Fool

Got $1,000? 2 Incredible Growth Stocks to Buy and Hold Forever ↗

July 14, 2024

These companies have what it takes to stand the test of time in a portfolio.

Via The Motley Fool

Forecasting The Future: 13 Analyst Projections For Vertex Pharmaceuticals ↗

July 11, 2024

Via Benzinga

Check Out What Whales Are Doing With VRTX ↗

July 10, 2024

Via Benzinga

Why the quality investor may take a look at NASDAQ:VRTX. ↗

July 03, 2024

Examining the Quality Attributes of NASDAQ:VRTX.

Via Chartmill

$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today ↗

July 01, 2024

Via Benzinga

The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 ↗

July 09, 2024

Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge.

Via InvestorPlace

Healthcare Stocks Continue To Lag The Market-Can Anything Help ? ↗

July 08, 2024

Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health.

Via Talk Markets

3 No-Brainer Stocks to Buy in July ↗

July 08, 2024

Investors shouldn't have to think too hard about these great stocks.

Via The Motley Fool

3 Pharma Stocks Already Ushering in the Next Biotech Boom ↗

July 08, 2024

So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider.

Via InvestorPlace

Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon). ↗

July 06, 2024

Vertex shares have advanced by triple digits over the past few years.

Via The Motley Fool

The 3 Best Biotech Stocks to Buy in July 2024 ↗

July 05, 2024

For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024.

Via InvestorPlace

1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever ↗

July 05, 2024

It's not too late to get in on the act.

Via The Motley Fool

Did Vertex Pharmaceuticals Just Invent the Next Ozempic? ↗

July 05, 2024

Vertex Pharmaceuticals likely has a breakthrough medicine on its hands.

Via The Motley Fool

Forget Eli Lilly: 3 Biotech Stocks to Buy Instead ↗

July 04, 2024

Eli Lilly is a good stock to buy, but these should be even better.

Via The Motley Fool

3 Top-Rated Gene Editing Stocks Actually Making Money ↗

July 03, 2024

Profitable gene editing stocks make increasingly compelling investments as therapies commercialize this year and beyond.

Via InvestorPlace

Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex

July 02, 2024

The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout.

Via MarketBeat

Topics ETFs

Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis

July 02, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

3 Under-the-Radar Biotech Stocks With Blockbuster Potential ↗

July 02, 2024

Are you looking to boost your portfolio with the best under-the-radar biotech stocks? Here are the top three.

Via InvestorPlace

Vertex to Announce Second Quarter 2024 Financial Results on August 1

July 01, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

3 Breakout Biotech Stocks on Track to Double by 2032 ↗

July 01, 2024

The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify.

Via InvestorPlace

Bull Market Buys: 2 Growth Stocks to Own for the Long Run ↗

July 01, 2024

The latest bull market has plenty of intriguing buying opportunities.

Via The Motley Fool

2 Superior Growth Stocks to Buy if You Have $1,000 Right Now ↗

June 28, 2024

Growth stocks with wide moats and strong financials can compound investor returns with time.

Via The Motley Fool

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗

June 28, 2024

These healthcare stocks have clear paths to growth over the next few years.

Via The Motley Fool

2 Healthcare Stocks That Are Screaming Buys in June ↗

June 28, 2024

These top healthcare stocks are no-brainer buys in 2024 and beyond.

Via The Motley Fool

You’ve Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever. ↗

June 27, 2024

Invest in the top biotech stocks to buy, as the sector pivots from pandemic-driven vaccine sales to solutions for chronic conditions.

Via InvestorPlace

This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

June 27, 2024

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vertex Pharmaceuticals (NQ:VRTX)

All News about Vertex Pharmaceuticals

Starting at $3.75/week.

Subscribe Today